536974-84-2

Basic information

• Product Name: Benzenemethanol, 3,5-dichloro-4-(phenylmethoxy)-
• CAS NO: 536974-84-2
• Molecular Formula: C14H12Cl2O2
• Molecular Weight: 283.154
• Mol File: 536974-84-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 3,5-dichloro-4-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 3,5-dichloro-4-(phenylmethoxy)-(536974-84-2)
• EPA Substance Registry System: Benzenemethanol, 3,5-dichloro-4-(phenylmethoxy)-(536974-84-2)

Safety Data

• Hazardous Substances Data: 536974-84-2(Hazardous Substances Data)

Usage

Class

Phenylmethyl ethers

Physical State

White crystalline solid

Molecular Weight

291.15 g/mol

Primary Use

Intermediate in pharmaceutical and agrochemical synthesis

Potential Applications

Various chemical and industrial processes

Caution

Handle with care due to potential health hazards if improperly managed

Upstream product

• 536974-83-1 4-benzyloxy-3,5-dichlorobenzoic acid methyl ester 
• 3337-59-5 methyl 3,5-dichloro-4-hydroxybenzoate 
• 100-39-0 benzyl bromide 

Downstream Products

• 536974-85-3 2-benzyloxy-5-bromomethyl-1,3-dichlorobenzene 
• 537676-36-1 4-[(4-benzyloxy-3,5-dichlorobenzyl)[1,2,4]triazol-4-ylamino]benzonitrile 

Relevant articles and documents

Dual aromatase-steroid sulfatase inhibitors

By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in'vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC 50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.